Diabetes Mellitus Type 2 as a Risk Factor and Outcome Modifier for Cryptococcosis in HIV Negative, Non-transplant Patients, a Propensity Score Match Analysis

Empreu sempre aquest identificador per citar o enllaçar aquest ítem http://hdl.handle.net/10045/138186
Información del item - Informació de l'item - Item information
Títol: Diabetes Mellitus Type 2 as a Risk Factor and Outcome Modifier for Cryptococcosis in HIV Negative, Non-transplant Patients, a Propensity Score Match Analysis
Autors: Kung, Vanessa M. | Ferraz, Carolina | Kennis, Matthew | Franco-Paredes, Carlos | Tuells, José | Vargas Barahona, Lilian | Shapiro, Leland | Thompson III, George R. | Chastain, Daniel B. | Henao-Martinez, Andres F.
Grups d'investigació o GITE: Salud Comunitaria (SALUD)
Centre, Departament o Servei: Universidad de Alicante. Departamento de Enfermería Comunitaria, Medicina Preventiva y Salud Pública e Historia de la Ciencia
Paraules clau: Cryptococcosis | Cryptococcus neoformans | Cryptococcus gattii | Type 2 diabetes mellitus | HIV-negative patients | Non-transplant patients
Data de publicació: 31-d’octubre-2023
Editor: Springer Nature
Citació bibliogràfica: Current Microbiology. 2023, 80:396. https://doi.org/10.1007/s00284-023-03512-9
Resum: Cryptococcosis is an opportunistic fungal infection of worldwide distribution with significant associated morbidity and mortality. HIV, organ transplantation, malignancy, cirrhosis, sarcoidosis, and immunosuppressive medications are established risk factors for cryptococcosis. Type 2 diabetes mellitus (DM2) has been hypothesized as a risk factor and an outcome modifier for cryptococcosis. We aimed to compare outcomes among HIV-negative, non-transplant (NHNT) patients with and without DM2. We queried a global research network to identify NHNT patients (n = 3280). We performed a propensity score-matched (PSM) analysis comparing clinical outcomes among cryptococcosis patients by DM status. We also characterize adults with cryptococcosis and DM2 as the only risk factor. After PSM, NHNT patients with DM2 were more likely to develop cognitive dysfunction [9% vs. 6%, OR 1.6; 95% CI (1.1–2.3); P = 0.01] but had similar mortality, hospitalization, ICU, and stroke risk after acquiring cryptococcosis when compared to NHNT patients without DM2. Pulmonary cryptococcosis was the most common site of infection. Among 44 cryptococcosis patients with DM2 as the only identifiable risk factor for disease, the annual incidence of cryptococcosis was 0.001%, with a prevalence of 0.002%. DM2 is associated with increased cognitive dysfunction risk in NHNT patients with cryptococcosis. It is rare for DM2 to be the only identified risk factor for developing cryptococcosis. Kidney disease, hyperglycemia, and immune dysfunction can increase the risk of cryptococcosis in patients with DM2.
URI: http://hdl.handle.net/10045/138186
ISSN: 0343-8651 (Print) | 1432-0991 (Online)
DOI: 10.1007/s00284-023-03512-9
Idioma: eng
Tipus: info:eu-repo/semantics/article
Drets: © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023
Revisió científica: si
Versió de l'editor: https://doi.org/10.1007/s00284-023-03512-9
Apareix a la col·lecció: INV - SALUD - Artículos de Revistas

Arxius per aquest ítem:
Arxius per aquest ítem:
Arxiu Descripció Tamany Format  
ThumbnailKung_etal_2023_CurrMicrobiol_final.pdfVersión final (acceso restringido)631,75 kBAdobe PDFObrir Vista prèvia
ThumbnailKung_etal_2023_CurrMicrobiol_preprint.pdfPreprint (acceso abierto)503,77 kBAdobe PDFObrir Vista prèvia


Tots els documents dipositats a RUA estan protegits per drets d'autors. Alguns drets reservats.